Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cognitive-behavioral therapy and paroxetine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cognitive-behavioral therapy and paroxetine-CR | DRUG | - |
Inclusion Criteria: * Male or female outpatients at least 18 years of age with a primary (the condition that is most central to the patient's current distress) psychiatric diagnosis of PTSD as defined by DSM-IV criteria * Patients must have remained symptomatic (CGI-S \> or = 3) and a score of at l...
Cognitive-behavioral therapy and paroxetine is used for post-traumatic stress disorder (PTSD). It is being studied as a combination treatment for PTSD that remains symptomatic after initial exposure therapy. The drug is a small molecule developed by GSK plc and is currently in Phase 2 clinical development.
Cognitive-behavioral therapy and paroxetine is developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The therapy combines cognitive-behavioral therapy with the drug paroxetine, and it is being investigated for the treatment of post-traumatic stress disorder.
Cognitive-behavioral therapy and paroxetine is in Phase 2 clinical development. It is an investigational therapy for post-traumatic stress disorder and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
Cognitive-behavioral therapy and paroxetine has been studied in one clinical trial, identified as NCT00215163. This Phase 2 trial, titled "Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy," was completed in the United States. The trial enrolled 17 participants aged 18 years and older.
Cognitive-behavioral therapy and paroxetine is a combination therapy that includes paroxetine, specifically paroxetine-CR (controlled release), along with cognitive-behavioral therapy. While paroxetine is a component of the treatment, the full therapy refers to the combined approach being studied for post-traumatic stress disorder.